The role of IgG hypersensitivity in the pathogenesis and therapy of depressive disorders

Nutritional Neuroscience

Volumn 20, Issue 2, 2017, Pages 110-118

  Karakuła Juchnowicz, Hanna ^a   Szachta, Patrycja ^b   Opolska, Aneta ^c   Morylowska Topolska, Justyna ^a   Gałęcka, Mirosława ^b   Juchnowicz, Dariusz ^c   Krukow, Paweł ^a   Lasik, Zofia ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Institute of Microecology   (Poland)

^c Department of Dietetics Higher School of Social Sciences ^*  (Poland)

Author keywords

Depression; Gluten sensitivity; IgG hypersensitivity; Inflammatory theory of depression; Leaky gut; Zonulin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIADIN; GLUTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NEUROTRANSMITTER; PROTEIN; PROTEINASE ACTIVATED RECEPTOR; SEROTONIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ZONULIN;

AMINO ACID METABOLISM; ARTICLE; AUTISM; CELIAC DISEASE; CYTOKINE RELEASE; DEPRESSION; DIET THERAPY; DISEASE ASSOCIATION; DYSBIOSIS; FOOD ALLERGY; GLUTEN FREE DIET; HUMAN; HYPERSENSITIVITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; THEORETICAL MODEL; TIGHT JUNCTION; ANIMAL; BIOLOGICAL MODEL; BLOOD; BRAIN; DEPRESSIVE DISORDER; ENTERITIS; IMMUNOLOGY; INTESTINE ABSORPTION; INTESTINE MUCOSA; METABOLISM; MULTIMODALITY CANCER THERAPY; NERVE CELL; PATHOPHYSIOLOGY; PERMEABILITY; PSYCHOLOGY; WHEAT ALLERGY;

ANIMALS; BRAIN; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DIET, GLUTEN-FREE; ENTERITIS; FOOD HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN G; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MODELS, IMMUNOLOGICAL; MODELS, NEUROLOGICAL; NEURONS; PERMEABILITY; WHEAT HYPERSENSITIVITY;

EID: 84978468540     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1179/1476830514Y.0000000158     Document Type: Article

References (130)

1. Wittchen HU. The burden of mood disorders. Science 2012;338:15.
2. Pużyński S. Choroby afektywne nawracające. In:Pużyński S, Rybakowski J, Wciórka J, (ed.) Psychiatria tom 2, Psychiatria kliniczna. Wrocław:Elsevier Urban & Partner; 2012. p. 305–75.
3. Anisman H. Inflaming depression. J Psychiatry Neurosci 2011;36:291–5.
4. Elomaa AP, Niskanen L, Herzig KH, Viinamäki H, Hintikka J. Elevated levels of serum IL-5 are associated with an increased likelihood of major depressive disorder. BMC Psychiatry 2012;12:2.
5. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression:intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008;29(1):117–24.
6. Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200.
7. Smith RS. The macrophage theory of depression. Med Hypotheses 1991;35:298–306.
8. Ryś A, Miodek A, Szemraj P, Kocur J. Immunological and endocrine aspects of pathogenesis of depression. Adv Psychiatry Neurol 2007;16(4):335–7.
9. Gołąb J, Jakóbisiak M, Lasek W. Immunology. Warszawa:PWN; 2004. p. 198–247
10. Ufnal M, Wolynczyk-Gmaj D. The brain and cytokines–the mutual origin of depression, obesity and cardiovascular diseases? Adv Hyg Exp Med 2011;65:228–35.
11. Refojo D, Liberman AC, Holsboer F, Arzt E. Transcription factor-mediated molecular mechanisms involved in the functional cross-talk between cytokines and glucocorticoids. Immunol Cell Biol 2001;79(4):385–94.
12. Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev 2007;18(1–2):45–56.
13. Dantzer R, Wollman E, Vitkovic L, Yirmiya R. Cytokines and depression:fortuitous or causative association? Mol. Psychiatry 1999;4:328–32.
14. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6:a meta-analysis. Psychosom Med 2009;71:171–86.
15. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446–57.
16. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999;40(4):171–6.
17. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009;66(3):287–92.
18. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med 2003;65(3):347–56.
19. Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 2010;197(5):372–7.
20. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007;29:147–55.
21. Loftis JM, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C:a 16-week prospective study. J Psychosom Res 2013;74(1):57–63.
22. Asnis GM, De La Garza R. Interferon-induced depression in chronic hepatitis C:a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006;40(4):322–35.
23. Leonard BE, Myint A. Changes in the immune system in depression and dementia:causal or coincidental effects? Dialogues Clin Neurosci 2006;8:163–74.
24. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines:a meta-analysis. Neuropsychopharmacology 2011;36(12):2452–9.
25. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness:animal and human studies. Curr Pharm Des 2005;11(8):963–72.
26. Lim W, Hong S, Nelesen R, Dimsdale JF. The association of obesity, cytokine levels, and depressive symptoms with diverse measures of fatigue in healthy subjects. Arch Intern Med 2005;165(8):910–5.
27. Schaefer M, Schmidt F, Neumer R, Scholler G, Schwarz M. Interferon-alpha, cytokines and possible implications for mood disorders. Bipolar Disord 2002;4(Suppl 1):111–3.
28. Khairova RA, Machado-Vieira R, Du J, Manji HK, :A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009;12:561–78.
29. Miller AH. Mechanisms of cytokine induced behavioral changes:psychoneuroimmunology at the translational interface. Norman Cousins Lecture. Brain Behav Immun 2009;23:149–58.
30. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ. Activation of central nervous system inflammatory pathways by interferon-alpha:relationship to monoamines and depression. Biol Psychiatry 2009;65(4):296–303.
31. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand 2005;112(2):93–6.
32. Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann NY Acad Sci 2010;1199:1–14.
33. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new ‘5-HT’ hypothesis of depression:cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:702–21.
34. Dienes KA, Hazel NA, Hammen CL. Cortisol secretion in depressed, and at-risk adults. Psychoneuroendocrinology 2013;38(6):927–40.
35. Kitagami T, Yamada K, Miura H, Hashimoto R, Nabeshima T, Ohta T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats:role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 2003;978(1–2):104–14.
36. Martin JL, Finsterwald C. Cooperation between BDNF and glutamate in the regulation of synaptic transmission and neuronal development. Commun Integr Biol 2011;4(1):14–6.
37. Anisman H. Cascading effects of stressors and inflammatory immune system activation:implications for major depressive disorder. J Psychiatry Neurosci 2009;34:4–20.
38. Dinan TG. Glucocorticoids and genesis of depressive illness a psychological approach. Br J Psychiatry 1994;164:365–71.
39. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004;29(10):1765–81.
40. Remlinger-Molenda A, Wójciak P, Michalak M, Rybakowski J. Activity of selected cytokines in bipolar patients during manic and depressive episodes. Psychiatr Pol 2012;46(4):599–611.
41. Raison LR, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011;13:467–75.
42. Severance EG, Alaedini A, Yang S, Halling M, Gressitt KL, Stallings CR, et al. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr Res 2012;138(1):48–53.
43. Bowling FG, Heussler HS, McWhinney A, Dawson PA. Plasma and urinary sulfate determination in a cohort with autism. Biochem Genet 2013;51(1–2):147–53.
44. Fasano A. Leaky gut and autoimmune diseases. Clin. Rev. Allergy Immunol 2012;42:71–8.
45. Rudzki L, Frank M, Szulc A, Gałęcka M, Szachta P, Barwinek D. From gut to depression–the role of intestinal barrier discontinuity and activation of the immune system in the depression inflammatory hypothesis. Neuropsychiatr Neuropsychology 2012;7(2):76–84.
46. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr 2005;94(4):386–93.
47. Odenwald MA, Turner JR. Intestinal permeability defects:is it time to treat? Clin Gastroenterol Hepatol 2013;11(9):1075–83.
48. Jiang Y, Guo C, Zhang D, Zhang J, Wang X, Geng C. The altered tight junctions:an important gateway of bacterial translocation in cachexia patients with advanced gastric cancer. J Interferon Cytokine Res 2014;34(7):518–25.
49. Cereijido M, Valdés J, Shoshani L, Contreras RG. Role of tight junctions in establishing and maintaining cell polarity. Annu Rev Physiol 1998;60:161–77.
50. Kojima T, Kokai Y, Chiba H, Yamamoto M, Mochizuki Y, Sawada N. Cx32 but not Cx26 is associated with tight junctions in primary cultures of rat hepatocytes. Exp Cell Res 2001;263:193–201.
51. Singh D, Solan JL, Taffet SM, Javier R, Lampe PD. Connexin 43 interacts with zona occludens-1 and -2 proteins in a cell cycle stage-specific manner. J Biol Chem 2005;280:30416–21.
52. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA 2009;106(39):16799–804.
53. Fasano A. Zonulin and its regulation of intestinal barrier function:the biological door to inflammation, autoimmunity, and cancer. Physiol. Rev 2011;91:151–75.
54. Pabijasz D. Ocena przepuszczalności jelitowej na podstawie stężenia zonuliny u dzieci z nieswoistymi zapaleniami jelit. Postępy Nauk Medycznych 2013;5:346–50.
55. El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 2002;123(5):1607–15.
56. Drago S, El Asmar R, Di Pierro M, Grazia Clemente M, Tripathi A, Sapone A, et al. Gliadin, zonulin and gut permeability:effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41(4):408–19.
57. Hart A, Kamm MA. Review article:mechanisms of initiation and perpetuation of gut inflammation by stress. Aliment Pharmacol Ther 2002;16(12):2017–28.
58. Lammers KM, Lu R, Brownley J, Lu B, Gerard C, Thomas K, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008;135(1):194–204.
59. Kiliaan AJ, Saunders PR, Bijlsma PB, Berin MC, Taminiau JA, Groot JA, et al. Stress stimulates transepithelial macromolecular uptake in rat jejunum. Am J Physiol 1998;275(5 Pt1):G1037–44.
60. Clemente MG, De Virgiliis S, Kang JS, Macatagney R, Musu MP, Di Pierro MR, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003;52:218–23.
61. Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 2006;55:1443–9.
62. Visser J, Rozing J, Sapone A, Lammers K, Fasano A. Tight junctions, intestinal permeability, and autoimmunity:celiac disease and type 1 diabetes paradigms. Ann NY Acad Sci 2009;1165:195–205.
63. Drago S, Congia M, Fasano A. Early effects of gliadin on enterocyte intracellular signaling involved in intestinal barrier function. Gut 2003;52:218–23.
64. MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005;307(5717):1920–5.
65. Bengmark S. Advanced glycation and lipoxidation end products–amplifiers of inflammation:the role of food. J Parenter Enteral Nutr 2007;31:430–40.
66. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 2005;1043:461–6.
67. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways:a dynamic duo. Annu Rev Physiol 2012;73:283–309.
68. Betanzos A, Javier-Reyna R, García-Rivera G, Bañuelos C, González-Mariscal L, Schnoor M, et al. The EhCPADH112 complex of Entamoeba histolytica interacts with tight junction proteins occludin and claudin-1 to produce epithelial damage. PLoS One 2013;8(6):e65100.
69. Kotler BM, Kerstetter JE, Insogna KL. Claudins, dietary milk proteins, and intestinal barrier regulation. Nutr Rev 2013;71(1):60–5.
70. Günzel D, Fromm M. Claudins and other tight junction proteins. Compr Physiol 2012;2(3):1819–52.
71. Van Itallie CM, Anderson JM. Claudin interactions in and out of the tight junction. Tissue Barriers 2013;1(3):e25247.
72. Ozawa T, Miyata M, Nishimura M, Ando T, Ouyang Y, Ohba T, et al. Transforming growth factor-beta activity in commercially available pasteurized cow milk provides protection against inflammation in mice. J Nutr 2009;139:69–75.
73. Sprong RC, Schonewille AJ, van der Meer R. Dietary cheese whey protein protects rats against mild dextran sulfate sodium-induced colitis:role of mucin and microbiota. J Dairy Sci 2010;93:1364–71.
74. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, et al. Occludin:a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993;123(6 Pt 2):1777–88.
75. Saitou M, Ando-Akatsuka Y, Itoh M, Furuse M, Inazawa J, Fujimoto K, et al. Mammalian occludin in epithelial cells:its expression and subcellular distribution. Eur J Cell Biol 1997;73(3):222–31.
76. Riba A, Cartier Ch, Bacquie V, Lencina C, Mallet V, Harkat Ch. Early maternal separation in mice triggered a specific IgG response against soluble food antigens. Gastroenterology 2013;144(5):S717.
77. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability:an overview. Gastroenterology 1995;108(5):1566–81.
78. Teixeira TF, Collado MC, Ferreira CL, Bressan J, Peluzio, Mdo C. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr Res 2012;32(9):637–47.
79. Alonso C, Vicario M, Pigrau M, Lobo B, Santos J. Intestinal barrier function and the brain-gut axis. In:Lyte M, Cryan JF, editors. Microbial endocrinology:the microbiota-gut-brain axis in health and disease. New York:Springer; 2014. pp. 73–113.
80. Moloney RD, Desbonnet L, Clarke G, Dinan TG, Cryan JF. The microbiome:stress, health and disease. Mamm Genome 2014;25(1–2):49–74.
81. Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linløkken A, Wilson R, et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil 2014;26(8):1155–62.
82. Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr 2006;25(6):514–22.
83. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use:report of the nomenclature review committee of the world allergy organization, October 2003. J Allergy Clin Immunol 2004;113(5):832–6.
84. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome:a randomised controlled trial. Gut 2004;53(10):1459–64.
85. Bentz S, Hausmann M, Piberger H, Kellermeier S, Paul S, Held L, et al. Clinical relevance of IgG antibodies against ood antigens in Crohn's disease:a double-blind cross-over diet intervention study. Digestion 2010;81(4):252–64.
86. Frank M, Ignyś I, Gałęcka M, Szachta P. IgG-dependent food allergy and its role in selected diseases. Pediatr Pol 2012;88(3):252–7.
87. O'Farrelly C, Kelly J, Hekkens W. Alpha gliadin antibody levels:a serological test for coeliac disease. Br Med J (Clin Res Ed) 1983;286:2007–10.
88. Beyazit Y, Sayilir A, Tas A, Kekilli M. IgA and IgG antibody testing for coeliac disease. Eur J Intern Med 2010;21(5):467–8.
89. Czarnobilska E, Obtułowicz K, Wsołek K. Type IV of hypersensitivity and its subtypes. Przegl Lek 2007;64(7–8):506–8.
90. Zuo XL, Li YQ, Li WJ, Guo YT, Lu XF, Li JM, et al. Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy 2007;37:823–30.
91. Owen J, Punt J, Stranford S. Kuby Immunology. 7th ed. New York:WH Freeman and Co.; 2013.
92. Chavez AM, Menconi MJ, Hodin RA. Cytokine-induced intestinal epithelial hyperpermeability:role of nitric oxide. Crit Care Med 1999;27(10):2246–51.
93. Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor–modulation. Am J Physiol Gastrointest Liver Physiol 2006;290:G496–G504.
94. Jackson JR, Eaton WW, Cascella NG, Fasano A, Kelly DL. Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity. Psychiatr Q 2012;83:91–102.
95. Carr AC. Depressed mood associated with gluten sensitivity–resolution of symptoms with a gluten-free diet. N Z Med J 2012;125(1366):81–2.
96. Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PH, Hadjivassiliou M, et al. Spectrum of gluten-related disorders:consensus on new nomenclature and classification. BMC Med 2012;10:13.
97. Leonard MM, Vasagar B. US perspective on gluten-related diseases. Clin Exp Gastroenterol 2014;7:25–37.
98. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease:an evolving spectrum. Gastroenterology 2001;120:636–51.
99. Schuppan D, Zimmer KP. The diagnosis and treatment of celiac disease. Dtsch Arztebl Int 2013;110(49):835–46.
100. Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, et al. Non-Celiac gluten sensitivity:the new frontier of gluten related disorders. Nutrients 2013;5(10):3839–53.
101. Sapone A. Gluten sensitivity:definition and diagnostic process. Forum 2011;3:4–6.
102. Catassi C. A new pathology is born:gluten sensitivity. Forum 2011;3:1–3.
103. Hadjivassiliou M, Grunewald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry 2002;72:560–3.
104. Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease:a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011;106(3):508–14.
105. De Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010;51(4):418–24.
106. Carta MG, Hardoy MC, Boi MF, Mariotti S, Carpiniello B, Usai P. association between panic disorder, major depressive disorder and celiac disease:a possible role of thyroid autoimmunity. J Psychosom Res 2002;53:789–93.
107. Ludvigsson JF, Reutfors J, Osby U, Ekbom A, Montgomery SM. Coeliac disease and risk of mood disorders–a general population-based cohort study. J Affect Disord 2007;99:117–26.
108. Ruuskanen A, Kaukinen K, Collin P, Huhtala H, Valve R, Maki M, et al. Positive serum antigliadin antibodies without celiac disease in the elderly population:does it matter? Scand J Gastroenterol 2010;45:1197–202.
109. Peters SL, Biesiekierski JR, Yelland GW, Muir JG, Gibson PR. Randomised clinical trial:gluten may cause depression in subjects with non-coeliac gluten sensitivity–an exploratory clinical study. Aliment Pharmacol Ther 2014;39(10):1104–12.
110. Volman JJ, Ramakers JD, Plat J. Dietary modulation of immune function by beta-glucans. Physiol Behav 2008;94:276–84.
111. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health:from Metchnikoff to modern advances:part II-contemporary contextual research. Gut Pathog 2013;5(3):1–14.
112. Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders:new insights into the gut microbiota. Curr Opin Pharmacol 2009;9:737–43.
113. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, et al. Prebiotic effects:metabolic and health benefits. Br J Nutr 2010;104(Suppl 2):S1–63.
114. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2:e1308.
115. Rapin JR, Wiernsperger N. Possible links between intestinal permeablity and food processing:a potential therapeutic niche for glutamine. Clinics (Sao Paulo) 2010;65(6):635–43.
116. Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 2011;141(5):769–76.
117. Kosińska A, Andlauer W. Modulation of tight junction integrity by food components. Food Res Int 2013;54(1):951–60.
118. Alpay K, Ertas M, Orhan EK, Üstay DK, Lieners C, Baykan B. Diet restriction in migraine, based on IgG against foods:a clinical double-blind, randomised, cross-over trial. Cephalalgia 2010;30(7):829–37.
119. Aydinlar EI, Dikmen PY, Tiftikci A, Saruc M, Aksu M, Gunsoy HG, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache 2013;53(3):514–25.
120. Szachta P, Frank M, Gałecka M, Ignyś I. Gastrointestinal tract disorders and nutritional therapy in children with autism spectrum disorders. Pediatr Pol 2014;89:269–76.
121. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders:their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 2005;51(2):77–85.
122. Knivsberg AM, Reichelt KL, Hoien T, Nodland M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 2002;5(4):251–61.
123. Millward C, Ferriter M, Calver S, Connell-Jones G. (2008). Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev. 2004;(2):CD003498.
124. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-free diet in autism:results of a preliminary double blind clinical trial. J Autism Dev Disord 2006;36(3):413–20.
125. Corvaglia L, Catamo R, Pepe G, Lazzari R, Corvaglia E. Depression in adult untreated celiac subjects:diagnosis by the pediatrician. Am J Gastroenterol 1999;94(3):839–43.
126. Pynnönen PA, Isometsa ET, Verkasalo MA, Kähkönen SA, Sipilä I, Savilahti E, et al. Gluten-free diet may alleviate depressive and behavioural symptoms in adolescents with coeliac disease:a prospective follow-up case-series study. BMC Psychiatry 2005;5:14.
127. Kleinman RE, Walker AW. Antigen processing and uptake from the intestinal tract. Clin Rev Allergy 1984;2:25–37.
128. Saavedra-Delgado AM, Metcalfe DD. Interactions between food antigens and the immune system in the pathogenesis of gastrointestinal diseases. Ann Allergy 1985;55(5):694–702.
129. Al-Sadi RM, Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol 2007;178:4641–9.
130. Lucas M, Chocano-Bedoya P, Shulze MB, Mirzaei F, O'Reilly ÉJ, Okereke OI, et al. Inflammatory dietary pattern and risk of depression among women. Brain Behav Immun 2014;36:46–53.